Skip to Main content Skip to Navigation
Journal articles

Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?

Abstract : Although CD95L (also known as FasL) is still predominantly considered as a death ligand that induces apoptosis in infected and transformed cells, substantial evidence indicate that it can also trigger non-apoptotic signaling pathways whose pathophysiological roles remain to be fully elucidated. The transmembrane ligand CD95L belongs to the tumor necrosis factor (TNF) superfamily. After cleavage by metalloprotease, its soluble form (s-CD95L) fails to trigger the apoptotic program but instead induces signaling pathways promoting the aggressiveness of certain inflammatory disorders such as autoimmune diseases and cancers. We propose to evaluate the various pathologies in which the metalloprotease-cleaved CD95L is accumulated and analyze whether this soluble ligand may play a significant role in the pathology progression. Based on the TNFα-targeting therapeutics, we envision that targeting the soluble form of CD95L may represent a very attractive therapeutic option in the pathologies depicted herein.
Document type :
Journal articles
Complete list of metadata
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Thursday, September 16, 2021 - 11:35:10 AM
Last modification on : Wednesday, October 20, 2021 - 1:31:26 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-01-26

Please log in to resquest access to the document



Keerthi Kurma, Andrea Boizard-Moracchini, Gael Galli, Mickael Jean, Pierre Vacher, et al.. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Elsevier, 2021, 1876 (2), pp.188596. ⟨10.1016/j.bbcan.2021.188596⟩. ⟨hal-03333846⟩



Record views